IPG Photonics issued a binding €300 million cash offer to acquire Lumibird Medical. The agreement includes additional performance-based earnouts of up to €50 million for 2026 and 2027. IPG will fund the transaction using existing cash on hand.
The deal combines IPG’s urology expertise with Lumibird’s established position in ophthalmology. Lumibird Medical generated €112.2 million in revenue during 2025. The acquisition increases IPG’s total addressable market by approximately $1 billion.
Management expects the transaction to be accretive to gross margin, EBITDA, and adjusted earnings per share. The deal remains subject to regulatory approvals and mandatory works council consultations.